Zdrowie i gospodarka · 29/05/1998

FDA Approves Supplemental New Animal Drug Application for Milbemycin Oxime Tablet in Cats

The US Food and Drug Administration (FDA) is updating its animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Novartis Animal Health US, Inc., which expands the indications for milbemycin oxime to include separate dosage and labeling for use in cats.